Search for: "Barr Pharmaceuticals Inc"
Results 141 - 160
of 162
Sorted by Relevance
|
Sort by Date
28 Oct 2011, 7:38 pm
Petitioners’ reply Amicus brief of International Municipal Lawyers Association Barr Laboratories, Inc. v. [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
4 Apr 2008, 1:00 am
: (IPBiz) Pharma & Biotech - Products Abilify (Aripiprazole) – Otsuka files US patent infringement suit against Teva over seeking approval for generic Abilify: (IP Law360), Aricept (Donepezil) – US federal judge grants Eisai’s request for preliminary injunction blocking Teva from marketing generic version of Aricept: (IP Law360), (Orange Book Blog), Carbatrol (Carbamazepine) – US federal judge delivers mixed ruling in Shire… [read post]
6 May 2010, 9:43 am
Teva Pharmaceuticals, USA, et al., 2009 WL 73274 (N.D.Ill. 03/16/09). [read post]
31 Jan 2011, 8:10 am
Barr Laboratories, Inc. 93 USPQ 2d 1417 (Fed. [read post]
31 Jan 2011, 8:10 am
Barr Laboratories, Inc. 93 USPQ 2d 1417 (Fed. [read post]
27 Sep 2009, 2:30 pm
As we noted in Genentech, Inc. v. [read post]
15 Jul 2010, 2:39 pm
Wyeth, Inc., 613 F. [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real story:… [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay generics in 2007:… [read post]
6 Jun 2008, 6:49 am
: (Spicy IP) Events 9-12 June: (US) Strategies for management of IP – Chicago: (IPR-Helpdesk), 11 June: US PLI ‘Advanced patent licensing 2008: What you need to know before licensing your patent’ – San Francisco: (Patent Docs), 11 June: MARQUES ‘First meeting with Spanish Judges of the Community Trade Mark Courts’ – Alicante: (Class 46), 13-14 June: Centre for European Economic Research conference on ‘The… [read post]
2 Nov 2018, 7:32 pm
Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307, 311-12 (5th Cir. 1989) (“Fortunately, we do not have to resolve any of the above questions [as to bias and confounding], since the studies presented to us incorporate the possibility of these factors by the use of a confidence interval. [read post]
10 Jun 2012, 1:09 pm
In some instances, especially in studies pharmaceutical adverse outcomes, there is the danger that the hypothesized outcome is also a feature of the underlying disease being treated. [read post]
31 Jan 2023, 6:36 pm
Ortho Pharmaceutical Corp., 788 F. 2d 741, 744–745 (11th Cir. 1986). [read post]
27 Jun 2008, 10:04 am
: (The Invent Blog), Impressive work on history of ‘Happy Birthday’ and copyright protection: (Innovationpartners), Gender and copyright: (Patry Copyright Blog) Events 1 July: US PLI: ‘Prior art & obviousness 2008: The PTO and CAFC perspective on patent law sections 102 & 103’ - New York: (Patent Docs), 1-2 July – C5 conference on intellectual asset management for high-tech industries – Paris: (c5-online.com), 2… [read post]
20 Jun 2008, 8:07 am
: (IP finance), Technical assistance a key point of discussion at TRIPS Council: (Intellectual Property Watch), WIPO turmoil as new DG’s future comes under threat: (IAM), WIPO to host inter-regional forum to explore strategies to enhance development and service-orientation of IP offices: (WIPO), Controversy over lack of transparency and overreaching enforcement provisions in ACTA: (Spicy IP), (Spicy IP) Global - Trade Marks / Domain Names / Brands World anti-counterfeiting day:… [read post]
5 Jul 2008, 11:05 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech… [read post]
2 May 2008, 7:00 am
: (Spicy IP), Ultracet (Tramadol) – Barr and Caraco win summary judgment that Ortho-McNeil’s formulation patent on Ultracet is invalid: (Orange Book Blog), Xopenex (Levosalbutamol) – US: Sepracor, Breath settle Xopenex patent fight: (IP Law360), (GenericsWeb), Africa African copyright & access to knowledge (ACA2K) project launched: (Michael Geist), (Afro-IP), Seven reasons why Prof Odek should be the next WIPO DG: (Afro-IP), … [read post]
12 Sep 2008, 2:33 pm
: (IP finance), MARQUES international advertising portal goes live: (Class 46) Global - Patents Using patent landscaping analytics to improve the quality of M & A decisions: a review of Cox Enterprises’ $300M purchase of Adify: (IP Asset Maximiser Blog), Universities reap royalty rewards; investors ignore IP at their peril: (IAM), Top IP-owning nations claim faster patent processing; near harmonisation deal: (Intellectual Property Watch), Bosch, Xerox and Dupont sign up… [read post]
1 Apr 2010, 1:42 pm
Novartis Pharmaceuticals Corp., 2000 WL 33915848 (E.D. [read post]
